» Articles » PMID: 39578340

Resveratrol: A Natural Compound Targeting the PI3K/Akt/mTOR Pathway in Neurological Diseases

Abstract

Neurological diseases (NDs), including neurodegenerative disorders and acute injuries, are a significant global health concern. The PI3K/Akt/mTOR pathway, a crucial signaling cascade, is responsible for the survival of cells, proliferation, and metabolism. Dysregulation of this pathway has been linked to neurological conditions, indicating its potential as a vital target for therapeutic approaches. Resveratrol (RSV), a natural compound found in berries, peanuts, and red grapes, has antioxidant, anti-cancer, and anti-inflammatory effects. Its ability to modulate the PI3K/Akt/mTOR pathway has been interesting in NDs. Studies have shown that RSV can activate the PI3K/Akt pathway, promoting cell survival and inhibiting apoptosis of neuronal cells. Its impact on mTOR, a downstream effector of Akt, further contributes to its neuroprotective effects. RSV's ability to restore autophagic flux presents a promising avenue for therapeutic intervention. Its anti-inflammatory properties suppress inflammatory responses by inhibiting key signaling molecules within the pathway. Additionally, RSV's role in enhancing mitochondrial function contributes to its neuroprotective profile. This study highlights RSV's potential as a multifaceted therapeutic agent in NDs, specifically by PI3K/Akt/mTOR pathway modulation. Additional investigation is required to optimize its therapeutic capacity in diverse neurological conditions.

References
1.
Feigin V, Vos T, Nichols E, Owolabi M, Carroll W, Dichgans M . The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2019; 19(3):255-265. PMC: 9945815. DOI: 10.1016/S1474-4422(19)30411-9. View

2.
Stefanidou M, Beiser A, Himali J, Peng T, Devinsky O, Seshadri S . Bi-directional association between epilepsy and dementia: The Framingham Heart Study. Neurology. 2020; 95(24):e3241-e3247. PMC: 7836659. DOI: 10.1212/WNL.0000000000011077. View

3.
Owolabi M, Leonardi M, Bassetti C, Jaarsma J, Hawrot T, Makanjuola A . Global synergistic actions to improve brain health for human development. Nat Rev Neurol. 2023; 19(6):371-383. PMC: 10197060. DOI: 10.1038/s41582-023-00808-z. View

4.
OMahony B, Nielsen G, Baxendale S, Edwards M, Yogarajah M . Economic Cost of Functional Neurologic Disorders: A Systematic Review. Neurology. 2023; 101(2):e202-e214. PMC: 10351557. DOI: 10.1212/WNL.0000000000207388. View

5.
Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, Suja V . Alzheimer's and Parkinson's disease therapies in the clinic. Bioeng Transl Med. 2023; 8(1):e10367. PMC: 9842041. DOI: 10.1002/btm2.10367. View